Vir Biotechnology VIR
NASDAQ VIR
$10.70 +0.06 (+0.52%)
As of: Sep 30, 2026 · 10:01 AM EDT

Vir Biotechnology (VIR) Receivables - Other (2021)

Updated

Vir Biotechnology's Receivables - Other was $112.5 million in Q1 2021.

Analysis

Vir Biotechnology (VIR) Receivables - Other (2021) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn
10 Vir Biotechnology 1.78 Bn 1.78 Bn 238.95 Mn
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2021 112.50 Mn
API Access

Vir Biotechnology Receivables - Other API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=receivables-other&ticker=VIR&period=max&api_key=YOUR_API_KEY